Salisbury, England, December 2012 – Enigma Diagnostics announces a grant award from the UK Government’s Biomedical Catalyst to develop deeply multiplexed PCR assays using its proprietary ResonSenseTM probing technology. Enigma will use the funding to demonstrate that ResonSenseTM can detect and differentiate many more target sequences in a single closed tube assay than conventional PCR chemistries.
The first ResonSenseTM test will be a multiplexed assay for the detection of Tuberculosis, covering human and animal variants along with resistant strains to both rifampicin & isoniazid treatments. The multi-drug-resistant tuberculosis (MDR-TB) assay will be translated onto the Company’s flagship “raw sample to result” ML system for use in decentralized clinical settings in resource poor areas where MDR-TB is an increasing healthcare problem.
Enigma is currently starting pre-clinical diagnostic verification of its influenza AB+RSV assay on the Enigma® ML and will use ResonSenseTM for complex infectious disease panel tests and cancer assays.
For more information, please see the attached release.
Media enquiries Contact: sonia.phacos@portongroup.com
